. 2019 Jun 7;16:68. doi: 10.1186/s12984-019-0533-9

Table 1.

Baseline parameters

Group	Age (yy ± s.d.)	Gender F/M	dd (yy ± s.d.)	H&Y (m ± s.d.)	MMSE (m ± s.d.)	CoM	Levodopa (mg ± s.d.)
RAS (n = 25)	70 ± 8	9/11	10 ± 3	3 ± 1	26 ± 3	None:4, DM:4, h:7, d:4, t:5, a:1	450 ± 55
non_RAS (n = 25)	73 ± 8	6/14	9.3 ± 3	3 ± 1	25 ± 3	None:5, DM:4, h:6, d:3, t:6, a:1	435 ± 49
p-value	0.7	0.4	0.3	0.1	0.2	0.7	0.7

Group

Age
(yy ± s.d.)

Gender
F/M

dd
(yy ± s.d.)

H&Y
(m ± s.d.)

MMSE
(m ± s.d.)

CoM

Levodopa (mg ± s.d.)

RAS

(n = 25)

70 ± 8

9/11

10 ± 3

3 ± 1

26 ± 3

None:4, DM:4, h:7, d:4, t:5, a:1

450 ± 55

non_RAS

(n = 25)

73 ± 8

6/14

9.3 ± 3

3 ± 1

25 ± 3

None:5, DM:4, h:6, d:3, t:6, a:1

435 ± 49

p-value

0.7

0.4

0.3

0.1

0.2

0.7

RAS Rhythmic auditory stimulation; dd disease duration; MMSE Mini-Mental State Examination; H&Y Hoehn and Yahr; CoM comorbidities (DM diabetes mellitus, h blood hypertension, d dyslipidemia, t tabagism, a alcoholism)